3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.
-
Upload
gyles-payne -
Category
Documents
-
view
217 -
download
0
Transcript of 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.
![Page 1: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/1.jpg)
3/98 medslides.com 1
Treatment ofPostmenoapausal
Osteoporosis
![Page 2: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/2.jpg)
3/98 medslides.com 2
What is Osteoporosis
• A disease that causes bones to lose mass, weaken and fracture
• affects 75 million people in Europe, Japan and the United States (over 28 million Americans)
• 1:2 women and 1:8 men are affected
• progression is slow, silent, painless
![Page 3: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/3.jpg)
3/98 medslides.com 3
Osteoporosis - definition
“a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration with a consequent increase in bone fragility and susceptibility to fracture”
Consensus Development Conference
Osteoporosis Int 1997;7:1-6
![Page 4: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/4.jpg)
3/98 medslides.com 4
Osteoporosis - definition
“a bone mineral density (T score) that is 2.5 SD below the mean peak value in young adults”
Working Group of the W.H.O.• useful for research but limited in clinical use
– ignores other determinants of bone strength– ignores higher risk of fracture in older women– failed to specify technique and site of measurement
J Bone Miner Res 1994; 9:1137-41
![Page 5: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/5.jpg)
3/98 medslides.com 5
Bone mineral densityZ Score
• Z score - a comparison with the mean value in normal subjects of the same age and sex (either at the lumbar spine or the proximal femur)
• Z score below -1 (lowest 25%)risk of fracture is approx doubled
• Z score below -2 (lowest 2.5%)risk of fracture is even higher
N Engl J Med 1998;338:736-746
![Page 6: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/6.jpg)
3/98 medslides.com 6
Bone Development
• Bones build mass beginning at birth and peaks by age 20-30
• bone growth promoted by adequate intake of calcium, vitamin D, and exercise
• bone begin to lose mass after age 30
![Page 7: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/7.jpg)
3/98 medslides.com 7
Building Strong Bones
• Adequate calcium intake– teenagers and postmenopasal women
not taking estrogen need 1,500 mg of calcium per day
– other adults need 1,000 mg per day
• Vitamin D
• Adequate exercise
![Page 8: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/8.jpg)
3/98 medslides.com 8
Osteoporosisclinical risk factors
• Female gender
• Caucasian or Asian race
• Thin body build
• Late onset of menstrual periods
• Early onset menopause
• Caffeine, Cigarettes and Alcohol
• A family history of osteoporosis
![Page 9: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/9.jpg)
3/98 medslides.com 9
Osteoporosisclinical risk factors
National Osteroporosis Foundation
• low body weight (<58 kg)• current smoking• first-degree relative with low-trauma
fracture• personal history of low-trauma fracture
Osteoporosis Int (in press)N Engl J Med 1998;338:736-746
![Page 10: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/10.jpg)
3/98 medslides.com 10
Osteoporosis - Risk factors
• Genetic factor– first-degree relative with low-trauma fracture
• Environmental factors– cigarette smoking– alcohol abuse– physical inactivity– thin habitus– diet low in calcium– little exposure to sunlight
N Engl J Med 1998;338:736-746
![Page 11: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/11.jpg)
3/98 medslides.com 11
Osteoporosis - Risk factors
• Menstral status– early menopause (before the age of 45 years)– previous amenorrhea (e.g., due to anorexia
nervosa, hyperprolactinemia)
• Drug therapy– glucocorticoids ( 7.5 mg/day for > 6 months)– antiepileptic drugs (e.g., phenytoin)– excessive substitution therapy (e.g., thyroxine)– anticoagulant drugs (e.g., heparin, warfarin)
N Engl J Med 1998;338:736-746
![Page 12: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/12.jpg)
3/98 medslides.com 12
Osteoporosis - Risk factors
• Endocrine disease– primary hyperparathryroidism– thyrotoxicosis– Cushing’s syndrome– Addison’s disease
• Rheumatologic diseases– rheumatoid arthritis– ankylosing spondylitis
N Engl J Med 1998;338:736-746
![Page 13: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/13.jpg)
3/98 medslides.com 13
Osteoporosis - Risk factors
• Hematologic disease– myltiple myeloma– systemic mastocytosis– lymphoma, leukemia– pernicious anemia
• Gastrointestinal diseases– malabsorption syndromes (e.g., celiac disease,
Crohn’s disease, surgery for peptic ulcer)– chronic liver disease (primary biliary cirrhosis)
N Engl J Med 1998;338:736-746
![Page 14: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/14.jpg)
3/98 medslides.com 14
Diagnostic Evaluation bone mineral density
• indications:– in women with strong risk factors
(see slides 10-13)– in those with osteoporosis-related
fractures (wrist, spine. Proximal femur, or humerus after mild or moderate trauma)
N Engl J Med 1998;338:736-746
![Page 15: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/15.jpg)
3/98 medslides.com 15
Diagnostic Evaluation bone mineral density
• techniques:– dual-energy x-ray absorptiometry (DEXA)
• proximal femur is most useful for predicting fractures
• lumbar spine is most useful for monitoring therapy
– single-energy x-ray absorptiometry– quantitative computed tomography– ultrasonography
N Engl J Med 1998;338:736-746
![Page 16: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/16.jpg)
3/98 medslides.com 16
Diagnostic Evaluation bone mineral density
• Diagnosis and treatment– T score < -2.5
need treatment to prevent fractures– T score < -2 ( at any site)
indicates accelerated bone lossneed to identify major risk factor
– T score < -1 (lumbar spine or prox femur) need to prevent further bone loss
N Engl J Med 1998;338:736-746
![Page 17: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/17.jpg)
3/98 medslides.com 17
Diagnostic Evaluation biochemical markers
• Bone formation– serum alkaline phosphatase– serum ostocalcin– serum C- and N-propeptides of type I
collagen
N Engl J Med 1998;338:736-746
![Page 18: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/18.jpg)
3/98 medslides.com 18
Diagnostic Evaluation biochemical markers
• Bone resorption– urinary excretion of
• pyridium cross-links of collagen (deoxypyridinoline)
• C- and N-telopeptides of collagen• galactosyl hydroxylysine• hydroxyproline
– serum tartrate-resistant acid phosphatase
N Engl J Med 1998;338:736-746
![Page 19: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/19.jpg)
3/98 medslides.com 19
Pathophysiology remodeling space
• space where some bone has been resorbed but not yet replaced during the remodeling process
• remodeling space is increased in postmenopausal osteoporosis
N Engl J Med 1998;338:736-746
![Page 20: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/20.jpg)
3/98 medslides.com 20
Pathophysiology remodeling space
• differential effects
• cancellous-bone loss– estrogen deficiency– glucocorticoid therapy
• cortical bone loss– parathyroid hormone excess
N Engl J Med 1998;338:736-746
![Page 21: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/21.jpg)
3/98 medslides.com 21
antiresorptive drugs
• antiresorptive drugs (estrogen, bisphosphonates, calcitonin) both the rates of bone resorption (in weeks) and formation (in months)
• bone mineral density is by 5-10 % for the first 2-3 years then plateaus; this reduces the risk of fracture by 50%
N Engl J Med 1998;338:736-746
![Page 22: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/22.jpg)
3/98 medslides.com 22
Bone formation drugs
• sodium fluoride and intermittent parathyroid hormone– stimulate bone formation– overfill resorption cavities– the increase in bone density continues
beyond two years
N Engl J Med 1998;338:736-746
![Page 23: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/23.jpg)
3/98 medslides.com 23
Effective of Drug Therapy onLumbar-Spine Bone Marrow Density
Placebo
Antiresorptive drug
Bone Formation drug
-1 0 1 2 3 4Year
0.9
1.0
1.1
1.2
N Engl J Med 1998;338:736-746
Lu
mb
ar-S
pin
e B
one
Min
eral
Den
sity
(g/
cm2 )
![Page 24: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/24.jpg)
3/98 medslides.com 24
Risk Factors for Bone Fracture
bone marrow density (BMD)
• high rate of bone turnover - the site of remodeling can break
• type of drug therapy - e.g., sodium fluoride increases BMD, but weakens the bone by being incorporated into the hydroxyapatite crystals of bone
N Engl J Med 1998;338:736-746
![Page 25: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/25.jpg)
3/98 medslides.com 25
Effects of Therapy on Lumbar-Spine BMD and Rate of Vertebral Fracture
Sodium fluorideAlendronate
-4 -3 -2 -1 0 1 2Lumbar-Spine Bone Mineral Density
Rel
ativ
e R
isk
of
Ver
teb
r al F
r ac t
ure
0
2
4
6
8
10
12
14
Estradioal
N Engl J Med 1998;338:736-746
![Page 26: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/26.jpg)
3/98 medslides.com 26
Current Therapiesestrogen-replacement
N Engl J Med 1998;338:736-746
• Benefits– relief of menopausal symptoms– prevention of bone loss and fractures
• increase in bone marrow density• decrease in bone turn over• lower relative risk (0.39) for vertebral fracture
– prevention of ischemic heart disease– prevention of dementia
![Page 27: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/27.jpg)
3/98 medslides.com 27
Current Therapiesestrogen-replacement
N Engl J Med 1998;338:736-746
• Risks– return of menstrual bleeding– risk of endometrial carcinoma– breast tenderness– risk of breast carcinoma– migraine– risk of DVT and pulmonary embolism
![Page 28: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/28.jpg)
3/98 medslides.com 28
Current Therapiesbiphosphonates
N Engl J Med 1998;338:736-746
• Stable analogues of pyrophosphate
• poorly absorbed from the intestine (<10%), must not be taken with food
• deposited in bone at the site of mineralization; apparently causing the death of osteoclasts which results in decreased bone resorption
![Page 29: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/29.jpg)
3/98 medslides.com 29
Current Therapiesbiphosphonates
N Engl J Med 1998;338:736-746
Etidronate low dose intermittent therapy:
400 mg /day x 2 wks, followedby 500 mg supplemental
calcium
per day x 11 wks
• increase in BMD of 4-8% in lumbar spine and 2% in femoral neck in 3 yrs
• decrease in vertebral fracture rate
![Page 30: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/30.jpg)
3/98 medslides.com 30
Current Therapiesbiphosphonates
N Engl J Med 1998;338:736-746
Alendronate 10 mg per day
• increase in BMD of 8.8% in lumbar spine and 5.9% in femoral neck in 3 yrs
• 48% relative decrease in new fractures and height loss
• associated with erosive esophagitis
![Page 31: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/31.jpg)
3/98 medslides.com 31
Current Therapiesbiphosphonates
N Engl J Med 1998;338:736-746
Alendronate
• to minimize the risk of esophagitis -take with a glass of water while upright at least 30 minutes before breakfast
• absolute contraindications: achalasia, esophageal strictures
• relative contraindications: reflux disease
![Page 32: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/32.jpg)
3/98 medslides.com 32
Current Therapiescalcium and vitamin D
BMJ 1994;308:1081-2
• French Study– 3270 institutionalized women– treated with calcium (1200 mg per day) and
vitamin D (800 IU per day) for 3 yrs– risk of hip fracture was reduced by 30%– reversal of secondary hyperparathyroidism– increase in BMD of the femoral neck
![Page 33: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/33.jpg)
3/98 medslides.com 33
Current Therapiescalcium and vitamin D
Ann Intern Med 1996;124:400-6
• Dutch Study– 2578 elderly women– treated with vitamin D (400 IU per day)
but no supplemental calcium– rate of hip fracture unchanged compared to
placebo– comment: the women were not housebound
![Page 34: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/34.jpg)
3/98 medslides.com 34
Current Therapiescalcium and vitamin D
N Engl J Med 1997;337:70-6
• U.S. Study– 389 men and women over age >63– treated with calcium (500 mg per day) and
vitamin D (700 IU per day)– decreased rate of nonvertebral fractures with
only a small increase in BMD of the lumbar spine (0.9%), femoral neck (1.2%), and total body (1.2%)
![Page 35: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/35.jpg)
3/98 medslides.com 35
Current Therapiescalcitonin
N Engl J Med 1997;337:70-6
• a 32-amino-acid peptide produced by the thyroid C cells
• inhibits the action of ostoclasts
• decreases bone resorption
![Page 36: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/36.jpg)
3/98 medslides.com 36
Current Therapiescalcitonin
N Engl J Med 1997;337:70-6
• Salmon or human calcitonin– 100 IU daily, subcutaneous or intramuscular– 200 IU daily, intranasal (salmon calcitonin)– suppositories are weak and poorly tolerated
• Benefits– increase BMD, decrease vertebral fracture
• Side effects– nausea, flushing, diarrhea, nasal discomfort
![Page 37: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/37.jpg)
3/98 medslides.com 37
Current Therapiesfluoride
Ostoporosis Int (in press)N Engl J Med 1997;337:70-6
Fluoride & Vertebral Osteoporosis Study
• 354 women with osteoporosis
• 2 year trial of sodium fluoride (50 mg/d) vs placebo
• significant increase in lumbar-spine BMD (10.8% vs 2.4%), but no effect on the rate of vertebral fracture
![Page 38: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/38.jpg)
3/98 medslides.com 38
Future Treatments
J Bone Miner Res 1996;11:835-42
• Estrogen-receptor modulators– has mixed estrogen-agonist and estrogen-
antagonist activity– raloxifene * shown to decrease bone
resorption and increase BMD in the lumbar-spine (2.4%), hip (2.4%), and body (2.0%)
– Others: tamoxifen, drolxifene, levormeloxifene
![Page 39: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/39.jpg)
3/98 medslides.com 39
Future Treatments
J Clin Endocrinol Metab 1997;82:620-8
• Parathyroid Hormone– daily injections stimulate bone formation– increase in BMD of the spine– effects on fracture rate not yet known
• Vitamin D analogues– strontium salts– ipriflavone
![Page 40: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/40.jpg)
3/98 medslides.com 40
ConclusionsTherapeutic Choices
N Engl J Med 1997;337:70-6
• Women most at risk should be treated– fracture with minimal or no trauma– those with low bone marrow density
• Acute phase of vertebral fracture– manage with analgesic drugs– lumbar-support corset– short period of bed rest and calcitonin
![Page 41: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/41.jpg)
3/98 medslides.com 41
ConclusionsTherapeutic Choices
N Engl J Med 1997;337:70-6
• Life style change– avoid heavy lifting– encourage exercise (such as walking)– avoid sedative drugs (may cause falls)– calcium intake increase to 1500 mg / day– avoid tobacco and excess alcohol– hip protectors (poor compliance)
![Page 42: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/42.jpg)
3/98 medslides.com 42
ConclusionsTherapeutic Choices
N Engl J Med 1997;337:70-6
• first choice: – estrogen-replacement therapy should be
given for at least 5 years– use preparation that do not cause uterine
bleed (continuous combined estro-progest)
• alternative choice:– biphosphonates (avoid SE of estrogen)– vitamin D for housebound patients
![Page 43: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/43.jpg)
3/98 medslides.com 43
ConclusionsTherapeutic Goal
N Engl J Med 1997;337:70-6
• to halve the risk of fracture
• a new fracture should not be considered a set back
• patients should be encouraged to continue therapy
![Page 44: 3/98medslides.com1 Treatment of Postmenoapausal Osteoporosis.](https://reader036.fdocuments.net/reader036/viewer/2022062516/56649e385503460f94b2914b/html5/thumbnails/44.jpg)
3/98 medslides.com 44
References
• Treatment of Postmenopausal Osteoporosis.Richard Eastell, MD. N Engl J Med 1998;338:736-746
• Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women.Chapuy MC et al. BMJ 1994;308:1081-2
• Vitamin D supplementation and fracture incidence inelderly persons. Lips P et al. Ann Inern Med 1996;124:400-6